XML 67 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Company Operations by Product, Customer and Geographic Area
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Company Operations by Product, Customer and Geographic Area Company Operations by Product, Customer and Geographic Area 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 
On June 30, 2020, the Company sold the Hospital Products. See Note 4: Disposition of the Hospital Products. The Company had no revenue during the twelve months ended December 31, 2021.

The following table presents a summary of total revenues by product for the twelve months ended December 31, 2020 and 2019:

 Revenue by Product: 20202019
Bloxiverz$2,201 $7,479 
Vazculep10,429 33,152 
Akovaz9,545 18,642 
Other159 (58)
Product sales$22,334 $59,215 


The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2020 and 2019: 
Revenue by Significant Customer:20202019
McKesson Corporation$5,758 $14,900 
Cardinal Health5,155 15,088 
AmerisourceBergen 3,155 12,059 
QuVa Pharma3,117 3,252 
Others5,149 13,916 
Product sales$22,334 $59,215 

All revenue earned during the years ended December 31, 2020 and 2019 was generated in the U.S.
Concentration of credit risk with respect to accounts receivable was limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of the Company’s customers and believes that it has adequately provided for any exposure to potential credit loss.

Currently, the Company is working with contract manufacturing organizations for the manufacture of FT218. Additionally, the Company purchases raw materials used in FT218 from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill, intangible assets and operating right-of use-assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2021, 2020, and 2019:
Long-lived Assets by Geographic Region: 202120202019
U.S.$19,605 $20,424 $22,254 
France— 11 196 
Ireland9,817 6,047 7,244 
Total$29,422 $26,482 $29,694